[
  {
    "ts": null,
    "headline": "Thermo Fisher Scientific Fuels the Future of Multi-omics Research with the Launch of Next-Generation Microarray Solution",
    "summary": "WALTHAM, Mass., October 15, 2025--Thermo Fisher Scientific, the world leader in serving science, has introduced the Applied Biosystems™ SwiftArrayStudio™ Microarray Analyzer, designed for fast and scalable sample analysis. In conjunction with two new arrays – the Applied Biosystems Axiom™ PharmacoPro™ Array and the Applied Biosystems Axiom PangenomePro Array – the analyzer combines four key genotyping processes into a single, integrated device, enabling researchers to cover the widest range of p",
    "url": "https://finnhub.io/api/news?id=8b3768b1f0b4ed2608b325700c97c2ea68e8e2ff12b6835bd44aacd6ae72158b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760559300,
      "headline": "Thermo Fisher Scientific Fuels the Future of Multi-omics Research with the Launch of Next-Generation Microarray Solution",
      "id": 137102024,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "WALTHAM, Mass., October 15, 2025--Thermo Fisher Scientific, the world leader in serving science, has introduced the Applied Biosystems™ SwiftArrayStudio™ Microarray Analyzer, designed for fast and scalable sample analysis. In conjunction with two new arrays – the Applied Biosystems Axiom™ PharmacoPro™ Array and the Applied Biosystems Axiom PangenomePro Array – the analyzer combines four key genotyping processes into a single, integrated device, enabling researchers to cover the widest range of p",
      "url": "https://finnhub.io/api/news?id=8b3768b1f0b4ed2608b325700c97c2ea68e8e2ff12b6835bd44aacd6ae72158b"
    }
  },
  {
    "ts": null,
    "headline": "Thermo Fisher Scientific (TMO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release",
    "summary": "Thermo Fisher (TMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finnhub.io/api/news?id=af8917a7dd0cfca7452139e7e6cef05d60c8ec884bbafaad920cf04eacd719f0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760536816,
      "headline": "Thermo Fisher Scientific (TMO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release",
      "id": 137094104,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "Thermo Fisher (TMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "url": "https://finnhub.io/api/news?id=af8917a7dd0cfca7452139e7e6cef05d60c8ec884bbafaad920cf04eacd719f0"
    }
  },
  {
    "ts": null,
    "headline": "Prenatal and Newborn Genetic Testing Analysis Report 2025: Market Led by Illumina, Thermo Fisher Scientific, & Agilent through Non-Invasive Technology, Prenatal Screening, and Expanding Global Access",
    "summary": "The prenatal and newborn genetic testing market is expanding due to technological advancements in non-invasive methods, rising awareness of genetic disorders, and supportive policies. Key opportunities include increased adoption of NGS and cfDNA technologies, growing demand in Asia Pacific, and insurance coverage expansion. Challenges persist with high costs and ethical issues.Dublin, Oct. 15, 2025 (GLOBE NEWSWIRE) -- The \"Prenatal and Newborn Genetic Testing Market Size, Market Share, Applicati",
    "url": "https://finnhub.io/api/news?id=49d447dd3a0a20101c11993f403a56e34783f4e3d3f8fbc3f7db1f7b9ed1811d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760529120,
      "headline": "Prenatal and Newborn Genetic Testing Analysis Report 2025: Market Led by Illumina, Thermo Fisher Scientific, & Agilent through Non-Invasive Technology, Prenatal Screening, and Expanding Global Access",
      "id": 137094105,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "The prenatal and newborn genetic testing market is expanding due to technological advancements in non-invasive methods, rising awareness of genetic disorders, and supportive policies. Key opportunities include increased adoption of NGS and cfDNA technologies, growing demand in Asia Pacific, and insurance coverage expansion. Challenges persist with high costs and ethical issues.Dublin, Oct. 15, 2025 (GLOBE NEWSWIRE) -- The \"Prenatal and Newborn Genetic Testing Market Size, Market Share, Applicati",
      "url": "https://finnhub.io/api/news?id=49d447dd3a0a20101c11993f403a56e34783f4e3d3f8fbc3f7db1f7b9ed1811d"
    }
  },
  {
    "ts": null,
    "headline": "Pharmaceutical Contract Manufacturing Market Research 2025-2030: GLP-1 Capacity Crunch, Expansion in Emerging Countries, Booming Radiopharmaceutical and Nuclear Medicine Segment Fuel Expansion",
    "summary": "The global pharmaceutical contract manufacturing market is set to hit USD 311.95 billion by 2030, climbing from USD 209.90 billion in 2025 at an 8.2% CAGR. Growth is driven by outsourcing for GLP-1, ADC programs, and biologics FDF manufacturing, which leads the market due to rising demands for biologics like monoclonal antibodies. North America, dominating the market, benefits from a strong regulatory landscape and advanced manufacturing tech. Key players like Thermo Fisher and Lonza leverage th",
    "url": "https://finnhub.io/api/news?id=7c45d0f53b2642abcf883ee16c824023dcd7e76b05716aa40b2f2504b25c8007",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760515440,
      "headline": "Pharmaceutical Contract Manufacturing Market Research 2025-2030: GLP-1 Capacity Crunch, Expansion in Emerging Countries, Booming Radiopharmaceutical and Nuclear Medicine Segment Fuel Expansion",
      "id": 137094106,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "The global pharmaceutical contract manufacturing market is set to hit USD 311.95 billion by 2030, climbing from USD 209.90 billion in 2025 at an 8.2% CAGR. Growth is driven by outsourcing for GLP-1, ADC programs, and biologics FDF manufacturing, which leads the market due to rising demands for biologics like monoclonal antibodies. North America, dominating the market, benefits from a strong regulatory landscape and advanced manufacturing tech. Key players like Thermo Fisher and Lonza leverage th",
      "url": "https://finnhub.io/api/news?id=7c45d0f53b2642abcf883ee16c824023dcd7e76b05716aa40b2f2504b25c8007"
    }
  },
  {
    "ts": null,
    "headline": "Is Thermo Fisher Scientific Attractively Priced After Recent $3.1 Billion Olink Acquisition?",
    "summary": "If you are weighing your next move with Thermo Fisher Scientific stock, you are not alone. Investors are sizing up their portfolios in light of the biotech industry's shifting landscape and the market's renewed appetite for stable growth. Thermo Fisher Scientific, with its most recent close at $525.83, has shown resilience, bouncing back 9.7% over the past month, even though it dipped 2.5% in just the last week. Year-to-date gains are a modest 0.6%, but stepping back, the five-year return, up...",
    "url": "https://finnhub.io/api/news?id=a5653b24fe53ba4d26a7cf152a9bef152d956b6cb8824bc4290deaf1fe79bb85",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760512053,
      "headline": "Is Thermo Fisher Scientific Attractively Priced After Recent $3.1 Billion Olink Acquisition?",
      "id": 137094107,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "If you are weighing your next move with Thermo Fisher Scientific stock, you are not alone. Investors are sizing up their portfolios in light of the biotech industry's shifting landscape and the market's renewed appetite for stable growth. Thermo Fisher Scientific, with its most recent close at $525.83, has shown resilience, bouncing back 9.7% over the past month, even though it dipped 2.5% in just the last week. Year-to-date gains are a modest 0.6%, but stepping back, the five-year return, up...",
      "url": "https://finnhub.io/api/news?id=a5653b24fe53ba4d26a7cf152a9bef152d956b6cb8824bc4290deaf1fe79bb85"
    }
  }
]